{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Paret C"],"funding":["Stiftung Kinderkrebsforschung Mainz","HI-TRON Mainz"],"pagination":["8431"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12428964"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(17)"],"pubmed_abstract":["High-risk (HR) neuroblastoma (NBL) patients often receive standardized treatment despite wide variations in clinical outcomes, underscoring the need for improved stratification tools. A distinguishing feature of NBL is the patient-specific expression of gangliosides (GGs), particularly GD2, which may serve as biomarkers. We analyzed GG profiles in 18 patient-derived tumors and 11 NBL cell lines using thin-layer chromatography and mass spectrometry. Expression of 0-, a-, and b-series GGs was examined and correlated with clinical risk, outcome, and gene expression data. Low-risk (LR) tumors expressed higher levels of complex b-series GGs. In HR tumors, five GG profiles (A-E) were identified. Profile A featured complex b-series GGs; B showed GD2 dominance; C showed synthesis arrest at GM3 or "],"journal":["International journal of molecular sciences"],"pubmed_title":["Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma."],"pmcid":["PMC12428964"],"funding_grant_id":["SKFM_01_2022","HITR-2021-14"],"pubmed_authors":["Wingerter A","Brignole C","Ustjanzew A","Seidmann L","Schwickerath P","Sandhoff R","Faber J","Ludwig J","El Malki K","Pastorino F","Wagner S","Sathyamurthy S","Roth W","Paret C"],"additional_accession":[]},"is_claimable":false,"name":"Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.","description":"High-risk (HR) neuroblastoma (NBL) patients often receive standardized treatment despite wide variations in clinical outcomes, underscoring the need for improved stratification tools. A distinguishing feature of NBL is the patient-specific expression of gangliosides (GGs), particularly GD2, which may serve as biomarkers. We analyzed GG profiles in 18 patient-derived tumors and 11 NBL cell lines using thin-layer chromatography and mass spectrometry. Expression of 0-, a-, and b-series GGs was examined and correlated with clinical risk, outcome, and gene expression data. Low-risk (LR) tumors expressed higher levels of complex b-series GGs. In HR tumors, five GG profiles (A-E) were identified. Profile A featured complex b-series GGs; B showed GD2 dominance; C showed synthesis arrest at GM3 or ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-04-08T19:14:38.609Z","creation":"2026-04-08T12:07:36.567Z"},"accession":"S-EPMC12428964","cross_references":{"pubmed":["40943355"],"doi":["10.3390/ijms26178431"]}}